Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Shares Outstanding (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Shares Outstanding for 4 consecutive years, with $700.0 as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding fell 99.84% to $700.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $700.0, a 99.84% decrease, with the full-year FY2024 number at $507520.0, up 62.09% from a year prior.
  • Shares Outstanding was $3.5 million for Q3 2025 at bioAffinity Technologies, up from $939138.0 in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $17.8 million in Q1 2025 to a low of $313114.0 in Q4 2023.
  • A 4-year average of $5.4 million and a median of $3.5 million in 2025 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: soared 1018.63% in 2023, then plummeted 99.84% in 2025.
  • bioAffinity Technologies' Shares Outstanding stood at $8.4 million in 2022, then tumbled by 96.26% to $313114.0 in 2023, then soared by 62.09% to $507520.0 in 2024, then tumbled by 99.86% to $700.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Shares Outstanding are $700.0 (Q3 2025), $939138.0 (Q2 2025), and $17.8 million (Q1 2025).